文献速递肝病消化道肿瘤与早癌

HILPDA通过限制缺氧状态下细胞内脂肪酸通量促进NASH驱动肝细胞癌发展

HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia.
PubMed 文献 · J Hepatol · 2023-04-13

该研究探讨缺氧诱导脂滴相关蛋白(HILPDA)在非酒精性脂肪性肝炎(NASH)驱动肝细胞癌(HCC)中的作用。人类NASH-HCC标本中HILPDA表达上调与生存期差强相关;体外缺氧和脂质负载下HILPDA促进肝癌细胞活力和3D上皮球体生长;肝细胞特异性Hilpda敲除小鼠NASH-HCC模型中肝脏脂肪变性和肿瘤发生减少但氧化应激增加。结论认为HILPDA是NASH肝脏微环境中的关键肿瘤代谢因子和潜在新治疗靶点。

要点

  • NASH-HCC患者中HILPDA表达上调与生存期差强相关。
  • 缺氧和脂质负载下HILPDA促进肝癌细胞活力和3D上皮球体生长。
  • 肝细胞Hilpda敲除小鼠NASH-HCC模型中脂肪变性和肿瘤发生减少但氧化应激增加。

核心结论

  • 肝细胞HILPDA是NASH肝脏微环境中的关键肿瘤代谢因子,代表潜在的新治疗靶点。

研究设计与样本

  • 研究评估了人NASH-HCC标本中HILPDA的临床意义(免疫组化和转录组学分析)。
  • 在暴露于游离脂肪酸及常氧或缺氧条件下的人HCC细胞和3D上皮球体中评估HILPDA的致癌效应。
  • 通过鸟枪法和靶向方法对野生型和HILPDA敲除HCC细胞进行脂质组学分析。
  • 野生型(Hilpdafl/fl)和肝细胞特异性Hilpda敲除(HilpdaΔHep)小鼠喂食西方饮食和饮水高糖并接受四氯化碳以诱导NASH驱动HCC。

主要发现

  • 在NASH-HCC患者中,HILPDA表达上调与生存期差强相关。
  • 在缺氧和脂质负载培养条件下,HILPDA促进人肝癌细胞活力和3D上皮球体生长。
  • 缺乏HILPDA触发多不饱和脂肪酸向膜磷脂流动和饱和脂肪酸向神经酰胺合成流动,在缺氧下加剧脂质过氧化和凋亡。
  • HILPDA缺陷诱导的凋亡可被神经酰胺合成的药理学抑制所逆转。
  • 在NASH-HCC实验小鼠模型中,HilpdaΔHep显示肝脏脂肪变性和肿瘤发生减少但肝脏氧化应激增加;单细胞分析支持肝脏HILPDA在保护HCC细胞和促进NASH中促肿瘤免疫微环境建立中的双重作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The prevalence of non-alcoholic steatohepatitis (NASH)-driven hepatocellular carcinoma (HCC) is rising rapidly, yet its underlying mechanisms remain unclear. Herein, we aim to determine the role of hypoxia-inducible lipid droplet associated protein (HILPDA)/hypoxia-inducible gene 2 (HIG2), a selective inhibitor of intracellular lipolysis, in NASH-driven HCC. METHODS: The clinical significance of HILPDA was assessed in human NASH-driven HCC specimens by immunohistochemistry and transcriptomics analyses. The oncogenic effect of HILPDA was assessed in human HCC cells and in 3D epithelial spheroids upon exposure to free fatty acids and either normoxia or hypoxia. Lipidomics profiling of wild-type and HILPDA knockout HCC cells was assessed via shotgun and targeted approaches. Wild-type (Hilpdafl/fl) and hepatocyte-specific Hilpda knockout (HilpdaΔHep) mice were fed a Western diet and high sugar in drinking water while receiving carbon tetrachloride to induce NASH-driven HCC. RESULTS: In patients with NASH-driven HCC, upregulated HILPDA expression is strongly associated with poor survival. In oxygen-deprived and lipid-loaded culture conditions, HILPDA promotes viability of human hepatoma cells and growth of 3D epithelial spheroids. Lack of HILPDA triggered flux of polyunsaturated fatty acids to membrane phospholipids and of saturated fatty acids to ceramide synthesis, exacerbating lipid peroxidation and apoptosis in hypoxia. The apoptosis induced by HILPDA deficiency was reversed by pharmacological inhibition of ceramide synthesis. In our experimental mouse model of NASH-driven HCC, HilpdaΔHep exhibited reduced hepatic steatosis and tumorigenesis but increased oxidative stress in the liver. Single-cell analysis supports a dual role of hepatic HILPDA in protecting HCC cells and facilitating the establishment of a pro-tumorigenic immune microenvironment in NASH. CONCLUSIONS: Hepatic HILPDA is a pivotal oncometabolic factor in the NASH liver microenvironment and represents a potential novel therapeutic target. IMPACT AND IMPLICATIONS: Non-alcoholic steatohepatitis (NASH, chronic metabolic liver disease caused by buildup of fat, inflammation and damage in the liver) is emerging as the leading risk factor and the fastest growing cause of hepatocellular carcinoma (HCC), the most common form of liver cancer. While curative therapeutic options exist for HCC, it frequently presents at a late stage when such options are no longer effective and only systemic therapies are available. However, systemic therapies are still associated with poor efficacy and some side effects. In addition, no approved drugs are available for NASH. Therefore, understanding the underlying metabolic alterations occurring during NASH-driven HCC is key to identifying new cancer treatments that target the unique metabolic needs of cancer cells.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Povero D, Chen Y, Johnson SM, et al. HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia. J Hepatol. 2023. PMID: 37061197. doi:10.1016/j.jhep.2023.03.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。